Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Fuji
McKesson
Accenture
Novartis
Merck
Boehringer Ingelheim
Cantor Fitzgerald
Mallinckrodt
AstraZeneca

Generated: January 22, 2018

DrugPatentWatch Database Preview

REVATIO Drug Profile

« Back to Dashboard

When do Revatio patents expire, and what generic alternatives are available?

Revatio is a drug marketed by Pfizer and is included in three NDAs.

The generic ingredient in REVATIO is sildenafil citrate. There are twenty drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the sildenafil citrate profile page.
Drug patent expirations by year for REVATIO
Pharmacology for REVATIO
Medical Subject Heading (MeSH) Categories for REVATIO

US Patents and Regulatory Information for REVATIO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer REVATIO sildenafil citrate FOR SUSPENSION;ORAL 203109-001 Aug 30, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer REVATIO sildenafil citrate SOLUTION;INTRAVENOUS 022473-001 Nov 18, 2009 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer REVATIO sildenafil citrate TABLET;ORAL 021845-001 Jun 3, 2005 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Queensland Health
Citi
Novartis
Colorcon
Harvard Business School
UBS
Mallinckrodt
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot